Sub Stoichiometric SPPS: A Genuinely Different Way to Green Peptide Manufacture

Solid‑phase peptide synthesis (SPPS) has been with us since Merrifield’s landmark 1963 work, but one feature has remained stubbornly unchanged: the need to use large excesses of amino acid building blocks to avoid deletion sequences. In their recent preprint, Nigenda et al. – 2026 – Sub-stoichiometric peptide synthesis, Nigenda and co‑workers argue convincingly that this “designed‑in waste” is no longer inevitable.

What makes this paper particularly interesting for process chemists is the shift in focus. Rather than concentrating solely on solvent substitution or recycling, the authors tackle what is often the largest hidden contributor to PMI and cost: the amino acid building blocks themselves. Using a variable bed flow reactor (VBFR), they demonstrate high‑purity peptide synthesis — even up to ~30‑mers — using stoichiometric and sub‑stoichiometric amounts of amino acid per coupling.

This matters enormously once you move beyond canonical residues. For non‑natural or custom‑made amino acids, the upstream synthesis can dominate both environmental footprint and economics. Wasting 60–90% of such materials is not just inefficient — it can make entire projects non‑viable. The VBFR approach shows holistic thinking: reducing waste at the coupling step avoids waste that was already “baked in” during amino acid synthesis.

The authors are also refreshingly willing to push the envelope, running what many would call “crazy” experiments to explore just how far the chemistry can be taken. Importantly, they back their extraordinary claims with detailed data — explicitly invoking Carl Sagan’s reminder that “extraordinary claims require extraordinary evidence”.

Finally, the paper itself is a pleasure to read: clear, candid and light‑hearted — a welcome change from the usual academic tone. If even half of that survives peer review, it will remain a standout contribution.

Bottom line: for anyone thinking seriously about the cost, sustainability and future scalability of peptide manufacture, this work deserves close attention.